Biotechnology
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIRT) using SIR-Spheres®Y-90 resin microspheres in China was successfully performed ...
2021-10-11 20:00
1622
Sai Life Sciences presents mid-term report on Sai Nxt initiative; reveals upsurge in capabilities
- Completes two-thirds of its investment target of US$150M - Demonstrates a leap forward in capabilities across all focus areas – People, Processes, and Infrastructure HYDERABAD, India, Oct. 11, 2021 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development and Manufac...
2021-10-11 16:50
2437
18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR™ Presented as Late Breaking Trial at VIVA
GENEVA, Oct. 11, 2021 /PRNewswire/ -- 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance's n...
2021-10-11 08:00
761
Sequential Skin raise US $1.65M in oversubscribed seed round to revolutionise skin health with their novel skin microbiome testing kit
LONDON, Oct. 11, 2021 /PRNewswire/ -- Sequential Skin Ltd
2021-10-11 06:00
2158
ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Conference
WOODINVILLE, Wash. and SUZHOU, China, Oct. 7, 2021 /PRNewswire/ -- ProfoundBio announces that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for Cancer Res...
2021-10-08 11:39
1786
Breakthrough for medtech pioneer: Syntellix receives product approval for India, opening up fast-growing market with 1.38 billion people
Syntellix CEO Claassen: "Greatest and most important success in the company's history" - Indian CDSCO grants approvals for five MAGNEZIX® product families - The Era of Magnesium for orthopaedics and traumatology now also begins in India - Subcontinent will be the world's most populous growth m...
2021-10-07 22:08
2244
Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-driven Cancers
HOUSTON and SINGAPORE, Oct. 7, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the presentation of pre-clinical data on novel biomarkers for HER3-driven cancers at the...
2021-10-07 21:03
1646
Deep Longevity Launches Longevity Medicine Course for Physicians with Industry Experts
HONG KONG, Oct. 7, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK)'s Deep Longevity, Inc, a company acquired on14 December 2020 which develops artificial intelligence to track human aging and ...
2021-10-07 15:30
10161
Research on Using Fluid Biomarkers to Advance Drug Treatments and Therapies for Alzheimer's, Traumatic Brain Injury, Concussion, and Other Neurodegenerative Diseases Presented at World Congress of Neurology 2021 by Neuroscientist Henrik Zetterberg
LONDON, Oct. 7, 2021 /PRNewswire/ -- New developments in the field of blood biomarkers for brain diseases including traumatic brain injury (TBI), and neurodegenerative diseases such as Alzheimer's, were unveiled during three lectures at the 25th BiennialWorld Congress of Neurology, October 3–7, 2...
2021-10-07 12:02
1944
Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis
LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire/ --
Debiopharm (www.debiopharm.com
2021-10-07 06:00
1823
Amplo Biotechnology Closes Series Seed Financing to Advance Gene Therapies for The Treatment of Neuromuscular Junction Disorders
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Amplo Biotechnology, a privately held US-based biotech focused on developing AAV (Adeno-associated Virus)-based gene therapies for diseases affecting the neuromuscular junction, today announced the successful closing of an undisclosed Series Seed financing. ...
2021-10-06 23:30
1385
BICO launches the S.NEST, a high throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows
TAIPEI, Oct. 6, 2021 /PRNewswire/ -- CYTENA Bioprocess Solutions, a BICO company, has launched the S.NEST™, a state-of-the art microbioreactor that maximizes cell growth while monitoring and analyzing cell conditions from start to finish. Well-known for combining innovative bioscience technologie...
2021-10-06 12:00
1868
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
ROSCREA, Ireland and FREIBURG, Germany, Oct. 5, 2021 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal ("GI") disorders, announced today that it has entered into a Licensing and C...
2021-10-05 20:10
2573
NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference
SHELTON, Conn., Oct. 5, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, presented an update of its Pan-Coronavirus COVID-19 Drug Development Program at t...
2021-10-05 18:45
10760
GenScript establishes Korean legal entity and accelerates sales activities
SEOUL, South Korea, Oct. 5, 2021 /PRNewswire/ -- GenScript, a global biotech company, recently completed the establishment of a legal entity called "GenScript Biotech Korea Ltd." and began to strengthen its sales activities in Korea in earnest. GenScript Biotech Korea Ltd. has built a nest at IK...
2021-10-05 09:00
4594
Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC
SHANGHAI and SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, whi...
2021-10-05 01:08
1442
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-10-04 21:24
9589
Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award
LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
2021-10-04 15:00
1289
World's Leading Neuroscientists Unveil Research on COVID-19's Impact on the Brain, Understanding Migraine Pathophysiology, Solving the Mystery of Sleep, Biomarkers in Traumatic Brain Injury and More at 25th Biennial World Congress of Neurology from October 3-7
LONDON, Oct. 2, 2021 /PRNewswire/ -- The impact COVID-19 has on the brain, understanding migraine pathophysiology, solving the mystery of sleep by "Lighting Up the Brain," blood biomarkers for traumatic brain injury and more groundbreaking research will be unveiled by the world's leading neurosci...
2021-10-02 12:10
4427
CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021
* Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And the 9-month duration of response (DOR) rate was 100% ...
2021-10-02 08:30
8914
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 320 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
9673
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
5856
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
5506
Sobha Developers bring to Singapore an Exclusive Dubai Property Showcase
2024-05-11 17:48
4495
